Wei Guo1,2, Dahao Yang3, Dengxuan Wu4, Huixia Liu1, Shiqun Chen2, Jin Liu2, Li Lei2, Yong Liu2, Lifen Rao1, Li Zhang1. 1. Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. 2. Department of Cardiology, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. 3. Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen 518000, China. 4. Department of Cardiology, Panzhihua Central Hospital, Panzhihua 617000, China.
Abstract
BACKGROUND: Although serum uric acid (UA) was regarded to be involved in cardiovascular disease, the role of serum UA (SUA) as a risk factor in acute myocardial infarction (AMI) is controversial. We investigated whether hyperuricemia was linked with long-term mortality in patients with AMI who underwent percutaneous coronary intervention (PCI). METHODS: Patients with AMI who received PCI were consecutively included. The definition of preprocedural hyperuricemia was a SUA level >7 mg/dL (417 mmol/L) in males and >6 mg/dL (357 mmol/L) in females. All-cause mortality was assessed during 2.3-year median follow up period. RESULTS: One thousand and five patients with AMI undergoing PCI were enrolled in a single center study, 307 (30.5%) patients had hyperuricemia. After adjusting for potential confounding factors, the multivariable analysis indicated that preprocedural hyperuricemia was related to an increased risk of all-cause mortality during the 2.3-year follow-up (HR: 1.97; 95% CI: 1.11-3.49; P=0.019). CONCLUSIONS: Preprocedural hyperuricemia, independently from chronic kidney disease (CKD), is a significant and independent predictor of long-term mortality for patients with AMI who underwent PCI. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Although serum uric acid (UA) was regarded to be involved in cardiovascular disease, the role of serum UA (SUA) as a risk factor in acute myocardial infarction (AMI) is controversial. We investigated whether hyperuricemia was linked with long-term mortality in patients with AMI who underwent percutaneous coronary intervention (PCI). METHODS: Patients with AMI who received PCI were consecutively included. The definition of preprocedural hyperuricemia was a SUA level >7 mg/dL (417 mmol/L) in males and >6 mg/dL (357 mmol/L) in females. All-cause mortality was assessed during 2.3-year median follow up period. RESULTS: One thousand and five patients with AMI undergoing PCI were enrolled in a single center study, 307 (30.5%) patients had hyperuricemia. After adjusting for potential confounding factors, the multivariable analysis indicated that preprocedural hyperuricemia was related to an increased risk of all-cause mortality during the 2.3-year follow-up (HR: 1.97; 95% CI: 1.11-3.49; P=0.019). CONCLUSIONS: Preprocedural hyperuricemia, independently from chronic kidney disease (CKD), is a significant and independent predictor of long-term mortality for patients with AMI who underwent PCI. 2019 Annals of Translational Medicine. All rights reserved.
Authors: Mahmut Akpek; Mehmet G Kaya; Huseyin Uyarel; Mikail Yarlioglues; Nihat Kalay; Ozgur Gunebakmaz; Orhan Dogdu; Idris Ardic; Deniz Elcik; Omer Sahin; Abdurrahman Oguzhan; Ali Ergin; Charles M Gibson Journal: Atherosclerosis Date: 2011-07-22 Impact factor: 5.162
Authors: Jacek Kowalczyk; Pawel Francuz; Ryszard Swoboda; Radoslaw Lenarczyk; Beata Sredniawa; Adam Golda; Tomasz Kurek; Michal Mazurek; Tomasz Podolecki; Lech Polonski; Zbigniew Kalarus Journal: Nephron Clin Pract Date: 2010-05-21
Authors: Abbas Dehghan; Mandy van Hoek; Eric J G Sijbrands; Albert Hofman; Jacqueline C M Witteman Journal: Diabetes Care Date: 2007-10-31 Impact factor: 19.112
Authors: Mehmet G Kaya; Huseyin Uyarel; Mahmut Akpek; Nihat Kalay; Mehmet Ergelen; Erkan Ayhan; Turgay Isik; Gokhan Cicek; Deniz Elcik; Omer Sahin; Said M Cosgun; Abdurrahman Oguzhan; Mehmet Eren; C Michael Gibson Journal: Am J Cardiol Date: 2011-11-17 Impact factor: 2.778
Authors: Claudio Borghi; Enrico Agabiti Rosei; Thomas Bardin; Jesse Dawson; Anna Dominiczak; Jan T Kielstein; Athanasios J Manolis; Fernando Perez-Ruiz; Giuseppe Mancia Journal: J Hypertens Date: 2015-09 Impact factor: 4.844
Authors: Mehmet Kanbay; Mark Segal; Baris Afsar; Duk-Hee Kang; Bernardo Rodriguez-Iturbe; Richard J Johnson Journal: Heart Date: 2013-01-23 Impact factor: 5.994